• 9 November 2006
  • News
  • By


Novel anti

Novel anti-psoriatic medication launched in India

Skin diseases are some of the most sensitive medical conditions for patients, affecting their quality of life and self esteem. Psoriasis is a chronic skin disease affecting about two percent of the population. The name derives from the Greek word 'psora' which means itch. Psoriasis arises when skin cells renew themselves too quickly. Psoriatic skin produces new cells more than four times as quickly as normal skin.Psoriasis can have many expressions. Most commonly, coin-shaped red, thick and scaly patches which, when scraped or scratched, show fine silvery scales. It usually appears on the upper body, elbows and knees but may also affect the scalp and nails. The psoriatic patches can feel very uncomfortable, both because of the itch and because of the look.

Win-Medicare, a Delhi-based pharmaceutical company, recently launched Daivobet, a world-renowned anti-psoriatic medication, manufactured by Denmark-based LEO Pharma, a global leader in the field of dermatology. Daivobet is a new topical formulation combining two active ingredients calcipotriol and bethamethasone dipropionate. It was recently approved by the USFDA as the only combination of a vitamin D analogue and a corticosteroid, which is proven to be one of the most effective and safe topical treatments for psoriasis available.

Surjit S Aurora, vice president, Win-Medicare, said, "Two-third of the patients in clinical trials with Daivobet showed marked improvement in or clearance of psoriasis after four weeks of treatment. Seeing the success rate of the product, we have entered into the marketing alliance with LEO Pharma to bring Daivobet to India. Daivobet will be available across the country through retailers and ethical promotion to dermatologists and we are confident that Daivobet will be successful here too."

Dr Harvey Lui, professor and head of the department of dermatology and skin science, University of British Columbia, who is an advisor to LEO Pharma, said, "There is a huge disparity in the treatment options for psoriasis in India as compared to those available in North America and Europe. The most commonly used treatment for psoriasis is steroids, which can become harmful with prolonged use. Daivobet represents a novel development that combines two active components in a safe and reliable formulation. I am confident that dermatologists and patients in India will welcome the introduction of this new tool to our therapeutic armamentarium for psoriasis."

Hans Christian Hansen, regional marketing manager, LEO Pharma Asia Pte Ltd, said, "Daivobet is the first and only product to combine a vitamin A analogue and a corticosteroid in one tube. Studies have shown that Daivobet is significantly more effective than either of the ingredients alone and the clinical data suggest that Daivobet is probably the most powerful topical product available for the treatment for psoriasis. In the Daivobet formulation, calcipotriol is dissolved in an oil which is mixed with white vaseline. Betamethasone dipropionate in a microcrystalline form is dispersed in petrolatum and then mixed with white vaseline. The formulation ensures that both ingredients are released sufficiently high concentrations without being inactivated. This new principle is unique and patented (patent pending)."

The calcipotriol in the ointment treats the overactive skin cells and normalizes the skin's growth, while the bethamethasone dipropionate relieves the redness, itching and irritation of the skin. Daivobet is to be applied once a day. Since it is cosmetically well accepted, one can wear usual clothes without the fear of stains. In India, Daibovet will be available in 15g pack, priced at Rs 998. Currently it is available worldwide in 60 countries including countries like the UK, USA, Canada, Thailand, Malaysia and Singapore.

Namratha Jagtap


Industry urges removal of anomalies in duty structure

The Indian biotechnology industry has made wide-ranging recommendations for bringing about regulatory and fiscal changes to remove procedural and other impediments in the critical sector.

Industry representatives, who met the Indian Sub-Group on Clinical Research and Transfer of Biomaterials under the Indo-US Joint Industry Working Group on Biotechnology under the aegis of FICCI, at a meeting chaired by the secretary, DBT, Dr MK Bhan, suggested that there was need for removal of anomalies in duty structure between public and private sector, and evolving procedures for easy clearance of materials for R&D. As many important items are under restrictions for import, it was suggested that NABL accredited laboratories be allowed to import any quantity of material for R&D.

Industry expressed concern at the 37 percent duty on instruments, which makes R&D more expensive. India pays 37 percent plus 27 percent on the list price. It was observed that most of the equipment for biotechnology and medical research does not attract any basic customs duty. However, additional customs duty, educational cess and cumulative additional cess (16+2+2) are charged. It was suggested that there should be no excise duty charged on these equipment.

The industry noted that the cost of chemicals and reagents sold by the US companies in India was much higher (up to 200 percent than in the US. Suggestions were made that the government may consider providing relief to Indian companies by giving a blanket permission, up to Rs 1 crore, for import of lab consumables to recognized R&D set-ups.

A number of steps were suggested for customs procedural simplification to avoid delays in clearances including procurement certificate for bonded warehouse and issue of block procurement certificate to start-ups, in addition to the facilities already extended to EOUs as per the circular of June 1, 2006. Other suggestions included simplification of customs' procedure including customs load, post facto clearance for dispatch, and use of products on receipt by CROs and easy clearance of materials for R&D.


Merck, Glenmark to collaborate on DPPIV Inhibitor for Type 2 diabetes

Merck KGaA and Glenmark Pharmaceuticals SA (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL), have entered into an agreement for Glenmark's DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes in phase II of clinical development. The transaction is expected to close this year upon approval of the exclusive license to GRC 8200 by the US antitrust agencies under the HSR Act.

Under the agreement, Merck KGaA will develop, register and commercialize GRC 8200 for markets in North America, Europe and Japan, while Glenmark will retain commercialization rights for India. The partners will share commercialization rights for other markets in the remainder of the world. Merck KGaA will bear the cost of all ongoing studies and will be responsible for planning, managing and sponsoring all development activities in the future.

The value of all payments to Glenmark could total up to €190 million, including a €25 million upfront payment and various milestone payments upon successful development and launch of mono-therapy and combination products based on GRC 8200. Upon commercial launch, Glenmark will supply the active ingredient to Merck and will receive royalties on net sales of the product.

Glenn Saldanha, MD and CEO of GPL, said, "This deal is in line with our strategy to collaborate with global partners for our new chemical entities program. The DPPIV inhibitor market is expected to be highly competitive and we are delighted to partner with Merck. Within the scientific community, it is widely expected that DPPIV inhibitors will be used in combination with other anti-diabetics. Existing and pipeline drugs from Merck KGaA are excellent candidates for the development of combinations and this would prove a significant advantage for both partners."


Global pharma to invest $150 million in India, China by 2010: E&Y

International pharma companies are increasingly bullish on investment prospects in China and India. They are expected to invest in excess of $150 million in both countries by 2010, according to the Ernst & Young Global Pharmaceutical Report.

The report further noted that several global companies have either established or plan to set up research & development (R&D) and/or manufacturing facilities in these two countries.

Utkarsh Palnitkar, national health sciences industry leader, Ernst & Young, said, "The Indian pharmaceutical industry is at the crossroads: on the one hand, opportunities are emerging in the developed markets, while on the other, the domestic market is becoming increasingly challenging following the introduction of the product patent regime. To counter the ageing product basket that will slowly but surely be a factor some years down the line, companies have ventured into discussions on licensing, co-marketing/co-development deals as well as other agreements."

The report noted that the R&D credit in India has emerged as the most appealing amongst financial instruments to attract foreign investment, as highlighted by over 62 percent of respondents. But better tax incentives are needed. Lesser number of pharma companies as compared to non-pharma companies, i.e., less than 1/3rd of respondents believed that the two countries' favorable tax terms were appealing or beneficial.

The report also highlights the continued importance of the generics industry. India will remain a market dominated by branded generics, as patented drugs that account for less than 2 percent will grow to only about 7 percent by 2015. The global generics market is expected to grow at a healthy pace to estimated $70 billion, doubling its size by 2010-2011. Contributing to this growth are factors including an aging population, pressure on governments to contain healthcare costs, pressures on policymakers in developing countries to increase access to drugs, and scores of upcoming patent expirations.


"India has skills and scalability to move to next levels"

"India's IT and biochemistry skills made it an ideal destination for sourcing informatics and research chemistry. And it can leverage on specific opportunities in generic space, contract manufacturing, contract research, offshoring and other services," said Huzaifa Khorakiwala, executive director, Wockhardt.

Speaking at the Pharmaceutical Leadership Summit in Mumbai, Huzaifa Khorakiwala, said, "Indian has moved up the value chain from chemicals to APIs to generics in regulated markets to specialty products. Now companies are focusing on R&D based products. And it has positioned it self to grow into a major center for biotechnology on the basis of low cost, global market opportunity. It now needs to evaluate future strategies considering the India advantage. Hence the thrust should be on the key areas which will drive the India life sciences industry such as drug discovery and development, manufacturing and supply chain, sales and marketing, enterprise management and support and healthcare."

The global pharma outsourcing market is estimated at $46 billion (includes contract manufacturing - $ 26 billion, contract research, custom synthesis and drug discovery -$10 billion and contract clinical trials - $10 billion.) "India has the size, skills and scalability to move to next levels," he said.

Quoting the IMS health, he said, "In 2010, nearly 50 percent of all new approved pharmaceuticals will be of biotechnological origin. The market for biopharmaceuticals is going to double from $44.3 billion in 2005 in the next four years mainly because of increasing in licensing by big pharma. Even the Indian biopharma market is expected to increase significantly in the coming years."

Mashelkar stresses on funding for BT

Mashelkar stresses on funding for BT

As seen in other parts of the world, biotechnology has immense growth potential in India, but for new companies making a foray into the sector, there is hardly any seed funding available. To address this gap, the government will soon set up a fund to finance start-ups in the biotechnology sector.

"We are negotiating with the World Bank for a loan of half a billion dollars and a part if this will be for early stage funding. This will be on the lines of the TDICI Fund, which was also a World Bank funded initiative for technology entrepreneurs," said RA Mashelkar, director general of Council for Scientific and Industrial Research (CSIR) at the Hi-Tech Pune conference on IT and BT on October 27, 2006.

Mashelkar also traced issues related to the sector in the country. "Our future is bright in biotechnology as both central and certain state governments are upbeat about the possibilities in the sector. But there are certain concerns, which will have to be addressed so as to have an edge in the international biotechnology scene,'' he said.

The first issue for the sector, according to him, were multiple regulators in the sector. "Though the talk of single window clearance is going on, it is still an illusion. However, the process to set up a National Biotechnology Authority as a single regulator is on,'' said Mashelkar.

On the controversies relating to Genetically Modified (GM) crops, Mashelkar said the policy on the matter has to be reviewed. "Globally, it is seen that governments either take a permissive or preventive stand on the issue. The correct approach is to strike a balance between them. It is imperative that in sectors like agri-biotechnology, GM crops will be required,'' he said.

According to him, developing countries were taking a lead in switching over to GM crops. "10 years ago, eight per cent of the developing countries had GM crops, but now, the number is as high as 34 per-cent,'' he said. In fact, with 7.2 million hectares under cultivation of GM crops, developing countries have overtaken developed countries, which have 6.1 million hectares under GM crops.

Mashelkar also expressed concern on the quality of many new emerging biotechnology institutes in the country. "I know of institutes which do not even have faculty. This is serious and one needs to have regulation in this area," he said.

He also said that unlike IT, there was hardly any hue and cry over companies shifting their operations to the Asia Pacific region. "This shifting will reduce costs of medicines and biotechnology products, which will ultimately benefit every one,'' Mashelkar said.


Dr Poonawalla receives Lifetime Achievement award

Dr Cyrus S Poonawalla, chairman of Serum Institute of India, India's largest vaccine manufacturer and No.1 Biotech company, received the Lifetime Achievement award in recognition of his commitment for making quality vaccines to protect the under-privileged children of the world at very affordable prices." The Chief Minister of Maharashtra, Vilas Rao Deshmukh, gave away the award to him at the 'Hi Tech Pune - Maharashtra 2006' conference held in Pune recently. Ashok Chavan, minister for industries, government of Maharashtra, Balasaheb Thorat, minister for agriculture, government of Maharashtra and Suresh Kalmadi, Member of Parliament, were present on the occasion.


EU Commission approves Novo Rapid

European healthcare company focusing on diabetes care, Novo Nordisk, has said that its drug combination Novo Rapid, used for management of Gestational Diabetes Mellitus (GDM) had been approved by the EU Commission.

Disclosing this to Cyber Media News in Chennai, Dr Anil Shinde, medical director at Novo Nordisk, said: "The EU Commission had approved the rapid-acting insulin combination for use by pregnant women with diabetes, after the study on 322 patients at over 90 centers in 17 countries, in the last four years, proved successful."

Quoting recent statistics from World Health Organization (WHO), he said that the prevalence of Gestational Diabetes Mellitus (GDM), in India women was put at 16.66 per cent and is said to be increasing every year. "Approximately seven percent of all pregnancies are complicated by GDM, and Indian women have 11-fold increased risk of developing glucose intolerance and other severe complications during pregnancy," he said further.

"As compared to Human Insulin, Novo Rapid controls the glucose levels and puts back the unbalanced biorhythmic cycles within the system, thus the risk of diabetes being passed on to the child by the mother is minimal in most cases," he said.

"With the EU Commission approval in place," Dr Shinde said, "Novo Rapid will now be available across the European Union."

"Novo Rapid would be the first modern insulin that will have a label stating that it can be used in pregnancy," he added.


New biotech products from Claris' stable

Ahmedabad-based Rs 400-crore Claris Lifesciences with a formidable presence in the domestic injectibles market is working on bolstering its biotech basket with one or two products slated for launch by this year-end.

The products will be related to cancer treatments and would significantly impact the company's current biotech offerings that are limited to only one product - EPO (Erythropoietin) and some research activities.

"Biotech is a very important market for many players around, but we want to concentrate on one area at a time wherein major investments have been pumped in recently," explained Nayan Rao, director, business development, Claris.

Besides the $20 million investment by Carlyle announced recently, the company is also raising Rs 100 crore via the ECB route from a foreign bank in another two-three weeks. A major chunk of this would go for capacity expansions to the tune of Rs.1000 crore (invoice value) by 2008-09, while the rest would go into new product facilities (renal care, disinfectants, oncology, cardiac care, etc.) and APIs (Active Pharmaceutical Ingredients). Also on the anvil are four-five products in NDDS (New Drug Delivery System) that makes up 60 per cent of the Claris business pie.

Generics is a key market for Claris given the seven-eight per cent turnover rate (of patented products to generics) that it wants to capitalize upon. While the company enjoys a 30-40 per cent share in domestic market, exports contribute 65 percent to its total business. It is going to ramp up its subsidiary count from 10 to 15 by adding Chile, Brazil, Mexico, China, and Russia.

The company has filed 40 products in Europe, nine ANDA (Abbreviated New Drug Applications) in US and 40 MAAs (Marketing Authorization Applications) in Europe and Australia and is expecting US FDA inspection by November.


HiMedia enters into joint distribution pact with VWR International

Mumbai-based HiMedia Laboratories has entered into a joint distribution agreement with VWR International to support the chemicals and laboratory supplies requirements of the rapidly expanding pharmaceutical and biotech industry in the subcontinent.

Dr GM Warke, CEO, HiMedia Laboratories, said, "VWR has a long standing history of being a global leader in the distribution of laboratory products in North America and Western Europe. We are proud to be selected as their strategic partner to bring its wide range, high quality products range to the laboratory community to India-and-given that VWR is already an exclusive distributor for HiMedia's innovative product line of Hi-Veg microbiological and cell culture media for North America, it makes for a terrific mutual relationship."

Sharing his views on the agreement, MK Sathya, vice president, Corporate Initiatives, VWR, said, "The Indian subcontinent is a growth market of strategic importance to VWR."

HiMedia has developed its own technology for manufacture of the culture media and succeeded in introducing over 2000 of them over the years. Its products are used in different parts of the world and compete favorably with other products of international repute.


TCG signs pact with KINFRA to set up biotech park

SPV Company, a wholly owned subsidiary of The Chaterjee Group Urban Infrastructure Hoarding (TCGUIH), has signed the lease deed with Kerala Industrial Infrastructure Development Corporation (KINFRA) for acquisition of 50 acres of land to set up a Biotech Park called "First Knowledge Park" within the KINFRA High-Tech Park at Cochin. With this, TCG becomes the first promoter in the country to have two major biotech parks in two different states, the first one being the International Biotech Park at Hinjewadi near Pune.

About 13 companies have signed MoUs with International Biotech Park for setting up labs at the park. Companies like Chembiotek, Advinus Discovery Labs have taken space at Genesis Square-a multi tenant campus for bioscience labs. Others like Centaur Pharma, Hikal Technologies, Chembiotek, Omni-Actives, Kard Scientific have opted for open and developed space. Advantium Pharma has taken space at Chrysalis Enclave - built to suit facility for research labs with a concept 'bench to the bed side'. The entire project to be developed in three phases will cost about Rs 250 crore.


Dr Reddy's settles litigation with GSK

Dr Reddy's Laboratories (DRL) has announced that it has settled a patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline's ImitrexR tablets.

DRL said in a statement that the terms of the settlement, which remain subject to government review, provide that Dr Reddy's may exclusively distribute an authorized generic version of sumatriptan succinate tablets (in the 25 mg, 50 mg and 100 mg strengths) in the US with an expected launch date late in the fourth quarter of calendar year 2008 ahead of the expiration of the pediatric exclusivity on 5037845 patent on February 06, 2009. Additional terms of the settlement agreement were not disclosed in the statement.

New Page 1

"Indian pharma must identify new opportunities to compete globally"

"In order to compete in the global arena, Indian pharma companies must offer something beyond the low-cost proposition. We must stop competing the way we are. There is a need to identify other areas, compete on quality, systems and superiority in order to convert 'Advantage India' into tangible benefits," emphasized Dr M Venkateswarlu, Drugs Controller General, Government of India.

In his inaugural address at the CII Pharma Summit 2006: "India Pharma Inc. – Competing Globally" held in Mumbai, Dr Venkateswarlu stressed on the need for regulatory authorities and industry stakeholders to interact and interface on a common platform facilitated to debate, discuss and evolve a consensus on pending issues like clinical trials. He also said that making research more attractive was critical for growth. Indian companies need to go beyond just the cardiac and diabetes segments and address lifestyle and old age diseases, which have great potential for growth.

Commenting on the need for regulations that enable such growth, he pointed out that there is a need for policies to be more proactive in nature. "They need to be transparent and practical so that even the layperson can understand them. Above all, regulations should be evolved by consensus of stakeholders and in harmony with global regulations," he added.


FDA approves new treatment for allergies

The Food and Drug Administration (FDA) approved Omnaris (ciclesonide) nasal spray, a new drug for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, commonly known as hay fever, in adults and children 12 years of age and older. Altana Pharma US Inc. of Florham Park, NJ manufactures Omnaris.

Although the precise way Omnaris works is unknown, the drug is a corticosteroid. Corticosteroids are hormone-like drugs that suppress the immune response.

Allergic rhinitis is the medical term for the inflamed, runny nose. Seasonal allergic rhinitis is the most common allergic disease. About 35 million Americans suffer from this condition. The ailment's classic symptoms are watery nasal discharge, and fits of sneezing, and itching that can affect not just the nose but the roof of the mouth, throat and the Eustachian tubes which connect the middle ear to the back of the throat.

The safety and efficacy of Omnaris nasal spray were studied in four randomized placebo controlled clinical trials ranging in duration from two weeks to a year. The studies assessed how well Omnaris treated symptoms (runny nose, nasal itching, sneezing, and nasal congestion) in patients with hay fever.


Panacea Biotec initiates development of dengue vaccine

Panacea Biotec has announced its initiative to develop and make a dengue vaccine for the global prevention of dengue infection/DHF, the second most widespread tropical disease after malaria. It is expected to market the vaccine in the next two-three years.

Rajesh Jain, joint managing director, Panacea Biotec Ltd said, "We have made an encouraging advance in the research and development of a preventive vaccine against dengue virus. Overall, the disease is a potential threat for close to half the world's population. The vaccine has been licensed to us by NIH, USA and is in the process of development. It would take another two to three years or so for the vaccine to get into the market, depending upon clearance from regulatory authorities. The vaccine will be effective against all the four strains of dengue virus and would cater to adult and children."

Dengue is a deadly disease carried by the Aedes mosquitoe that can cause fever, chills and skeletal pain. Some 2500 million people (2/5 of the world's population) are now at risk from dengue. As per World Health Organization (WHO) estimate, there may be 50 million cases of Dengue infection worldwide every year.


Janssen-Cilag to expand R&D activities in India

Janssen-Cilag, one of the world's leading research-based pharmaceutical companies, has announced plans to expand its research and development operations in India.

The company expects to increase the capacity of its research and early discovery laboratories in Mumbai from 50 to approximately 100 scientists by the end of 2007. In addition, its clinical pharmaceutical research operations will also expand, as part of the company's ongoing commitment to developing products for use in the Indian marketplace.


GSK leverages EvoGenix protein technology

EvoGenix has completed the first project in its collaboration with pharmaceutical company GlaxoSmithKline (GSK).

The completed project is the first of up to three projects that may be undertaken under the collaboration agreement. In reporting to GSK, EvoGenix noted its view that all goals set at the start of the project had been met in the work carried out by its R&D team. This is to be confirmed by GSK who are now undertaking internal evaluation of the results obtained.

Provision of the final report triggers a further payment to EvoGenix from GSK under the terms of the collaboration agreement between the two companies.

Under this agreement, which was signed late in 2005, EvoGenix used its protein optimization technology, EvoGene, to develop improved versions of a protein from the GlaxoSmithKline pharmaceutical pipeline.

GSK will be responsible for all subsequent development of the product, with EvoGenix eligible to earn a number of milestone payments as each product progresses through clinical testing towards the market. EvoGenix will also earn royalty payments on sales of products marketed successfully.

EvoGenix is employing its protein optimization methods in developing valuable protein therapeutics internally, as well as in its collaborations with GSK and CSL Limited.


New Plasmid Miniprep kits launched

Invitrogen Corporation, a leader in life science research, has launched ChargeSwitch-Pro Plasmid Miniprep kits. The kits apply ChargeSwitch Technology, the latest generation in nucleic acid purification chemistry, into the popular spin column format.

Invitrogen's ChargeSwitch Technology leverages the inherent negative charge of nucleic acids like DNA. ChargeSwitch is positively charged in acidic or low pH conditions and negatively charged in basic or high pH conditions.

Under low pH conditions, negatively charged DNA binds to the positively charged ChargeSwitch surface like a magnet and contaminants are washed away. When the pH of the ChargeSwitch surface is raised, the ChargeSwitch surface becomes neutral or negatively charged and the DNA is released away from the surface.

ChargeSwitch Technology was specifically developed to address the limitations of current purification technologies and is the only sample preparation method that does not use ethanol or chaotropic salts, two reagents that are known to inhibit enzymatic reactions and present storage, shipping, and handling challenges.

German database firm opens office in India

German database firm opens office in India

German biological database company has established its Indian branch office in Bangalore. This move is a part of the company's capacity expansion in the areas of database maintenance, product innovation and development of analysis tools in the Asian market. More than 60 scientists will be working in Bangalore in the future.

This newly established Indian Biobase subsidiary in Bangalore now joins the other two branch offices in Germany and in the US.

Michael Tysiak, CEO and CFO of Biobase said, "The launching of Biobase India introduces the next strategic step for us. Bangalore was very attractive to us as a well-known IT center, but also as the site of a number of internationally renowned bio-scientific research facilities. A group of very well-trained experts with high potential is stationed here. This was a required first step in facilitating the growth of our German organization."

Prof. E Wingender, president and CSO at Biobase, added, "Biobase India will play a large role in our future database production, both in the design of our existing portfolio and in the development of new products."


Solvay upgrades facility in India

Brussels-based biopharma major, Solvay group has decided to expand and upgrade its facilities in Panoli in Gujarat.

The expansion will result in the creation of a new, world-class production unit for polyetherether ketone (PEEK) and other materials in the ultra-performance segment of the specialty polymers business.

The installation will be built to provide for a natural expansion of production, resulting in a step-wise increase in capacity as warranted by demand. It will come on stream in the first quarter of 2008, with a production capacity of 500 metric tons per year of KetaSpire, the new line of PEEK products developed by Solvay Advanced Polymers.

Vincenzo Morici, general manager of the specialty polymers strategic business unit, Solvay said, "The expansion of the Panoli plant and the launch of our new KetaSpire PEEK materials are instrumental in our high and ultra-performance polymers strategy. With these expansion and upgrade plans, we can capitalise on the inherent strengths of Panoli, which contributed outstanding talent to the Group, as well as a prime location at the heart of the world's fastest- growing economies."

Solvay employs some 30,000 people in 50 countries. In 2005 its consolidated sales amounted to $10.75 billion generated by its three activity sectors, chemicals, plastics and pharmaceuticals.


Advanced Enzyme offers Systematic enzymes

Advancecd Enzyme Technologies, a leading enzyme companies in India, now offers Systematic enzymes-orphan drugs-that are natural, powerful and broad-spectrum biological response modifier for disease management, treatment and prevention for health management with side effects.

Speaking at the Pharmaceutical Leadership Summit, CL Rathi, chairman, Advanced Enzyme Technologies, said, "Enzymes as drugs have two important features that differ them from all other types of drugs. The enzymes often bind and act on their target with great affinity and specificity. They are act as catalyst and convert multiple target molecules to the desired products. These features make enzymes specific and potent body that small molecules cannot. These have resulted in the development of many enzyme drugs for a wide range of disorders. "

He further noted that there are many approved enzymes designed as orphan drugs in the USA. Companies like Enzon, Genzyme Corporation, Genentech, Orphan Medical, BioMarian Pharmaceutical have enzymes sold as orphan drugs under the trade names Adagen, Ceredase, Pulmozyme, Sucraid and Aldurazyme respectively.


Nano Interface Technology explores India operations

Washington DC-based Nano Interface Technology is looking to capture the country's booming orthopedic and dental implants market. The company's president and CEO, Dr C P Singh met with Ram Vilas Paswan, minister of chemicals, fertilizers and steel to explore the possibility of establishing a factory in India for orthopedic and dental implants.

India is projected to be the largest market for orthopedic and dental implants in the next five years. The hip, knee and dental implants have a worldwide market size of $15 billion dollar with growth rate of 15-25 percent. NITI has developed nanotechnology-derived economical ultra-pure coatings for orthopedic and dental implants.

Dr Singh also discussed business opportunity with Dr Ajay Kumar, president-elect of the Indian Medical Association which has 1,70,000 physicians and surgeons as members.

Dr Kumar said, "Nanotechnology can lead to paradigm shift in the market shares of the various existing medicines and devices due to the better performances by new formulations or devices. The first nanotechnology-based medicine, Neoral – a nano-size formulation of Cyclosporin, has been in the market for 10 years with market capitalization of $1 billion."

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email